Drug Trial Radar · NCT05517447
Extension Study to Assess Batoclimab in Participants With Thyroid Eye Disease
Last checked: Nov 19, 2026Latest source record: Apr 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
109
Actual
Start
Nov 6, 2022
Primary completion
Apr 2, 2026
Study completion Apr 2, 2026
Sponsor
- Lead sponsor
- Immunovant Sciences GmbHIndustry
- Sponsor type
- Industry
- First posted
- Aug 26, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a 2-cohort (observational and treatment cohort) extension study for participants completing feeder studies (IMVT-1401-3201 or IMVT-1401-3202). The observational cohort will assess the durability of proptosis response of feeder studies off treatment. The treatment cohort will evaluate the efficacy of batoclimab as assessed by proptosis responder rate.
Conditions
- Thyroid Eye Disease
Interventions
Observational cohort studyOther
Observational cohort study
BatoclimabDrug
Batoclimab is a fully human anti-neonatal fragment crystallizable receptor (FcRn) monoclonal antibody
Primary outcomes
What the sponsor says the trial is designed to measure.
- Duration of proptosis response off treatment in study eye in batoclimab responder participants in the feeder studiesTime frame: Up to Week 24
Locations
55 sites in 14 countries. Site status is shown where the registry gives one.
Site Number - 1520
Glendora, California
Site Number - 1501
Aurora, Colorado
Site Number - 1526
Livonia, Michigan
Site Number - 1513
Rochester, Minnesota
Site Number - 1540
Las Vegas, Nevada
Site Number - 1508
Houston, Texas
Site Number - 1558
Mesquite, Texas
Site Number - 1511
Morgantown, West Virginia
Site Number - 1518
Milwaukee, Wisconsin
Site Number - 7565
Sydney, Australia
Site Number - 4671
Bruges, Belgium
Site Number - 4672
Brussels, Belgium
Site Number - 4673
Brussels, Belgium
Site Number - 4670
Ghent, Belgium
Site Number - 3454
Tbilisi, Georgia
Site Number - 3455
Tbilisi, Georgia
Site Number - 3450
Tbilisi, Georgia
Site Number - 3451
Tbilisi, Georgia
Site Number - 7550
Budapest, Hungary
Site Number - 7552
Pécs, Hungary
Site Number - 4764
Afula, Israel
Site Number - 4761
Jerusalem, Israel
Site Number - 4762
Petah Tikva, Israel
Site Number - 4760
Ramat Gan, Tel Aviv, Israel
Site Number - 6207
Catania, Italy
Site Number - 6204
Milan, Italy
Site Number - 6203
Milan, Italy
Site Number - 6205
Naples, Italy
Site Number - 6209
Palermo, Italy
Site Number - 6201
Pisa, Italy
Site Number - 6202
Rome, Italy
Site Number - 9301
Ogre, Latvia
Site Number - 9300
Riga, Latvia
Site Number - 9302
Ventspils, Latvia
Site Number - 7570
Christchurch, New Zealand
Site Number - 3101
Krakow, Poland
Site Number - 3104
Lublin, Poland
Site Number - 3105
Lublin, Poland
Site Number - 3107
Gliwice, Silesian Voivodeship, Poland
Site Number - 1990
San Juan, Puerto Rico
Showing 40 of 55 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.